TBD

Plenary Lecture 6

GLP-1 receptor agonists have transformed cardiovascular prevention, but their impact on skeletal muscle — a metabolically active tissue critical to glucose homeostasis, insulin sensitivity, and cardiorespiratory fitness — demands attention. Epidemiological evidence links low muscle mass to adverse cardiovascular outcomes independent of adiposity, yet muscle preservation remains absent from most prevention frameworks. This presentation examines the cardiovascular case for integrating resistance exercise alongside pharmacotherapy, and explores how inequities in access to both GLP-1 therapies and structured lifestyle programs threaten to widen existing disparities in cardiovascular health.

Plenary Lecture 5

Women who experience pregnancy complications such as preeclampsia are at increased risk of cardiovascular diseases in later life, as are their offspring. Whether pregnancy complications are a cause of maternal and offspring CVD is still an area of active investigations. Evidence also suggests that obstetric history does not improve CVD risk stratification. The delivered placenta offers currently-untapped opportunities to identify subgroups of women and offspring at increased CVD risk later in life.

Plenary Lecture 4

TBD

Plenary Lecture 3

Variations in mortality among prefectures were examined by sociodemographic factors using ecological panel data analysis from the late 1990s to the mid-2010s. Statistically significant differences were observed in mortality from all causes, cancer, and stroke by per capita prefectural income in men and in mortality from all causes, cancer, and heart disease by the proportion of public assistance recipients in both sexes. In addition, the findings on mortality from all causes and cardiovascular diseases by areal deprivation and population density in a 30-year follow-up of the representative Japanese population will be presented briefly.

Plenary Lecture 2

GLP-1 receptor agonists and SGLT2 inhibitors have transformed cardiovascular prevention in type 2 diabetes, but whether these benefits extend to type 1 diabetes remains unknown. Because major outcome trials excluded people with type 1 diabetes, cardiovascular outcome data are lacking and safety concerns have hindered broader use. This presentation includes a series of target trial emulation studies aimed at addressing the evidence gap in cardiovascular prevention with GLP-1 receptor agonists and SGLT2 inhibitors, focusing on type 1 diabetes— a clinically important population with significant unmet need for strategies to improve cardiovascular outcomes.